Navigation Links
Orexigen Therapeutics Commends the Campaign to End Obesity's Report on Long-term Returns of Obesity Prevention Policies
Date:4/25/2013

SAN DIEGO, April 25, 2013 /PRNewswire/ -- Regarding the report "The Long Term Returns of Obesity Prevention Policies" unveiled this week by the Campaign to End Obesity (CEO), Orexigen Therapeutics, Inc. (Nasdaq: OREX) issued the following statement:

Orexigen commends CEO as well as the author of the report, Alex Brill , and the Robert Wood Johnson Foundation (RWJF) who funded the report, for this new research illustrating the importance of long-term budget impact analyses on preventive health policies, specifically those aimed at obesity. With obesity contributing over $200 billion annually to healthcare spending, Orexigen agrees that policymakers need thorough budgetary analyses that capture short and long-term impacts of obesity policy. A longer view may enable policymakers to have more information when making legislative decisions. Brill noted that the largest budgetary benefits from reducing the burden of obesity would be federal savings within the Medicare and Medicaid programs that would result from avoiding obesity-related diseases and co-morbidity.

"Today's report supports our belief that, while there are substantial near-term benefits of weight loss for obese patients, an even larger value should accrue to individuals and societies when health improvements are assessed over a longer period of time," said Orexigen CEO, Michael Narachi .

The report's author, Alex Brill , is a Research Fellow at the American Enterprise Institute and formerly counsel to the Simpson-Bowles Deficit Reduction Commission and chief economist and policy director to the House Ways and Means Committee. Mr. Brill also served on the President's Council of Economic Advisers under President George W. Bush . Mr. Brill has worked on a variety of economic and legislative policy issues, including dividend taxation, the alternative minimum tax, international tax policy, social security reform, defined benefit pension reform and U.S. trade policy.

The report may be found at the Campaign to End Obesity's website http://obesitycampaign.org/research.asp

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Contact: McDavid Stilwell , 858-875-8600

 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
2. Orexigen Therapeutics to Present at Upcoming Conferences
3. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
4. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
5. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
6. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
7. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
8. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
9. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
10. Aratana Therapeutics Adds To Drug Development Team
11. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):